Therapeutic | Empasiprubart |
Target | C2 |
Heavy Chain | EVQLVQSGAEVKKPGASVKVSCKASGYTFTDYNMDWVRQATGQGLEWIGDINPNYESTGYNQKFKGRATMTVDKSISTAYMELSSLRSEDTAVYYCAREDDHDAFAYWGQGTLVTVSS |
Light Chain | DNVLTQSPDSLAVSLGERATISCRASKSVRTSGYNYMHWYQQKPGQPPKLLIYLASNLKSGVPDRFSGSGSGTDFTLTISSLQAEDAATYYCQHSRELPYTFGQGTKLEIK |
100% seqID Fv Structure | 8acf [Fvs: HL], 8aci [Fvs: HL] |
99% seqID Fv Structure | None |
95-98% seqID Fv Structure | None |
100% seqID Structure | 8acf [Fvs: HL] |
100% seqID Structure | 8aci [Fvs: HL] |
Follow these links to our prediction tools:
Format | Whole mAb |
Isotype | G1 |
Highest Clinical Trial (Aug '24) | Phase-II |
Estimated Status (Aug '24) | Active |
Recorded Developmental Technology | |
INN Year Proposed | 2022 |
INN Year Recommended | None |
Companies Involved | arGEN-X, Broteio |
Conditions Approved | na |
Conditions Active | Multifocal motor neuropathy, Dermatomyositis, Kidney disorders, Motor neuron disease |
Conditions Discontinued | COVID-19 |
Notes |
Schneider, C., Raybould, M.I.J., Deane, C.M. (2022) SAbDab in the Age of Biotherapeutics: Updates including SAbDab-Nano, the Nanobody Structure Tracker. Nucleic Acids Res. 50(D1):D1368-D1372 [link]
SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]
Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]